A Safety and Tolerability Study of Jaktinib

Status:
Not yet recruiting

Trial end date:
2023-11-30

Target enrollment:

Participant gender:

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

Phase 1

Suzhou Zelgen Biopharmaceuticals Co.,Ltd